Protocols

Important Disclaimer: The information below is for educational purposes only and is not personalized medical advice. Always consult with a qualified healthcare provider before starting any treatment protocol. Individual dosing and administration should only be determined by a licensed medical professional based on your specific medical history and needs.

Limited Evidence Available

Based on the available literature search, there is extremely limited published evidence regarding specific dosing protocols for the combination of Tesamorelin + Ipamorelin + MOTS-c. Only one relevant publication was identified discussing peptide therapies for musculoskeletal applications, but it did not provide detailed protocol information for this specific combination.

Individual Peptide Context

While combination protocols are not well-documented in peer-reviewed literature, these peptides are sometimes used individually in clinical and research settings:

Tesamorelin: Typically studied as a growth hormone-releasing hormone analog
Ipamorelin: Investigated as a growth hormone secretagogue
MOTS-c: A mitochondrial-derived peptide being researched for metabolic effects

Protocol Information Gap

The lack of published clinical trials or detailed protocol studies for this specific three-peptide combination represents a significant evidence gap. Without peer-reviewed research establishing safety, efficacy, and optimal dosing parameters for this combination, specific administration protocols cannot be reliably recommended based on current scientific literature.

Healthcare providers considering peptide therapies should rely on individual peptide research, clinical judgment, and patient-specific factors when developing treatment approaches, while acknowledging the limited evidence base for combination protocols.

Tesamorelin + Ipamorelin + MOTS-c

Member access required